Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Aprocitentan
Aprocitentan
  • Aprocitentan

Aprocitentan NEW

Price Get Latest Price
Package 25kg
Min. Order: 25kg
Supply Ability: /
Update Time: 2025-11-05

Product Details

Product Name: Aprocitentan CAS No.: 1103522-45-7
Min. Order: 25kg Purity: 0.99
Supply Ability: / Release date: 2025/11/05

Pilot Scale

Company Profile Introduction

Dorra Pharma is a comprehensive pharmaceutical group integrating research and development, production, and sales. Our main product areas include pharmaceutical active ingredients and intermediates, cosmetic raw materials, pet pharmaceutical ingredients, and formulation products. We have established dual R&D centers in Nanjing and Taizhou, where we carry out a full range of work from laboratory research to pilot-scale development. The R&D centers are staffed with nearly 100 full-time researchers, having completed the development of over 300 compounds. We have a leading edge in core technologies such as bromination, enzyme/metal catalysis, nitration, hydrogenation, and continuous flow processes, and hold multiple invention patents. Our production bases in Hubei and Gansu have received certifications from major regulatory bodies both domestically and internationally. At Dorra, we are committed to the mission of "creating more valuable products for life and health," constantly striving for excellence and creating greater value for both our clients and our business!

You may like

Recommended supplier

Product name Price   Suppliers Update time
$53.00/1mg
VIP6Y
TargetMol Chemicals Inc.
2025-11-05
$0.00/1kg
VIP2Y
Shandong Huizhihan Supply Chain Co., Ltd
2024-12-11
$0.00/1g
VIP6Y
Jinan Jianfeng Chemical Co., Ltd
2024-05-28
  • Since: 2011-11-14
  • Address: 15 / F, Building J, Grand Himalaya, 9 Liuchao Road, Yuhuatai District, Nanjing
INQUIRY